Amyotrophy, cerebellar impairment and psychiatric disease are the main symptoms in a cohort of 14 Czech patients with the late-onset form of Tay-Sachs disease.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 02 12 2018
accepted: 06 05 2019
revised: 02 05 2019
pubmed: 12 5 2019
medline: 10 1 2020
entrez: 12 5 2019
Statut: ppublish

Résumé

Tay-Sachs disease (TSD) is an inherited neurodegenerative disorder caused by a lysosomal β-hexosaminidase A deficiency due to mutations in the HEXA gene. The late-onset form of disease (LOTS) is considered rare, and only a limited number of cases have been reported. The clinical course of LOTS differs substantially from classic infantile TSD. Comprehensive data from 14 Czech patients with LOTS were collated, including results of enzyme assays and genetic analyses. 14 patients (9 females, 5 males) with LOTS were diagnosed between 2002 and 2018 in the Czech Republic (a calculated birth prevalence of 1 per 325,175 live births). The median age of first symptoms was 21 years (range 10-33 years), and the median diagnostic delay was 10.5 years (range 0-29 years). The main clinical symptoms at the time of manifestation were stammering or slurred speech, proximal weakness of the lower extremities due to anterior horn cell neuronopathy, signs of neo- and paleocerebellar dysfunction and/or psychiatric disorders. Cerebellar atrophy detected through brain MRI was a common finding. Residual enzyme activity was 1.8-4.1% of controls. All patients carried the typical LOTS-associated c.805G>A (p.Gly269Ser) mutation on at least one allele, while a novel point mutation, c.754C>T (p.Arg252Cys) was found in two siblings. LOTS seems to be an underdiagnosed cause of progressive distal motor neuron disease, with variably expressed cerebellar impairment and psychiatric symptomatology in our group of adolescent and adult patients. The enzyme assay of β-hexosaminidase A in serum/plasma is a rapid and reliable tool to verify clinical suspicions.

Sections du résumé

BACKGROUND BACKGROUND
Tay-Sachs disease (TSD) is an inherited neurodegenerative disorder caused by a lysosomal β-hexosaminidase A deficiency due to mutations in the HEXA gene. The late-onset form of disease (LOTS) is considered rare, and only a limited number of cases have been reported. The clinical course of LOTS differs substantially from classic infantile TSD.
METHODS METHODS
Comprehensive data from 14 Czech patients with LOTS were collated, including results of enzyme assays and genetic analyses.
RESULTS RESULTS
14 patients (9 females, 5 males) with LOTS were diagnosed between 2002 and 2018 in the Czech Republic (a calculated birth prevalence of 1 per 325,175 live births). The median age of first symptoms was 21 years (range 10-33 years), and the median diagnostic delay was 10.5 years (range 0-29 years). The main clinical symptoms at the time of manifestation were stammering or slurred speech, proximal weakness of the lower extremities due to anterior horn cell neuronopathy, signs of neo- and paleocerebellar dysfunction and/or psychiatric disorders. Cerebellar atrophy detected through brain MRI was a common finding. Residual enzyme activity was 1.8-4.1% of controls. All patients carried the typical LOTS-associated c.805G>A (p.Gly269Ser) mutation on at least one allele, while a novel point mutation, c.754C>T (p.Arg252Cys) was found in two siblings.
CONCLUSION CONCLUSIONS
LOTS seems to be an underdiagnosed cause of progressive distal motor neuron disease, with variably expressed cerebellar impairment and psychiatric symptomatology in our group of adolescent and adult patients. The enzyme assay of β-hexosaminidase A in serum/plasma is a rapid and reliable tool to verify clinical suspicions.

Identifiants

pubmed: 31076878
doi: 10.1007/s00415-019-09364-3
pii: 10.1007/s00415-019-09364-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1953-1959

Subventions

Organisme : Univerzita Karlova v Praze
ID : UNCE 204064
Organisme : Univerzita Karlova v Praze
ID : PROGRES Q26/LF1
Organisme : Ministerstvo Zdravotnictví Ceské Republiky (CZ)
ID : RVO-VFN 64165/2012

Références

Eur J Pediatr. 2000 Dec;159 Suppl 3:S192-5
pubmed: 11216898
Isr Med Assoc J. 2004 Feb;6(2):107-11
pubmed: 14986470
Genet Med. 2005 Feb;7(2):119-23
pubmed: 15714079
Genet Med. 2009 Jun;11(6):425-33
pubmed: 19346952
Hum Mutat. 2010 Nov;31(11):1240-50
pubmed: 20672374
Surv Ophthalmol. 2014 Jan-Feb;59(1):64-76
pubmed: 24011710
Science. 1989 Mar 17;243(4897):1471-4
pubmed: 2522679
Orphanet J Rare Dis. 2015 Apr 17;10:45
pubmed: 25896637
Br J Psychiatry. 1989 Sep;155:410-3
pubmed: 2611559
BMJ Case Rep. 2016 Mar 31;2016:
pubmed: 27033294
Pract Neurol. 2017 Oct;17(5):396-399
pubmed: 28739864
JIMD Rep. 2018;41:17-23
pubmed: 29214523
Am J Med Genet. 1986 May;24(1):179-96
pubmed: 2939718
Neurology. 1979 Jun;29(6):848-54
pubmed: 572006
JAMA. 1993 Nov 17;270(19):2307-15
pubmed: 8230592
J Neuropsychiatry Clin Neurosci. 1998 Winter;10(1):10-9
pubmed: 9547461

Auteurs

Helena Jahnová (H)

Department of Paediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 2, 120 00, Prague 2, Czech Republic.

Helena Poupětová (H)

Department of Paediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 2, 120 00, Prague 2, Czech Republic.

Jitka Jirečková (J)

Department of Paediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 2, 120 00, Prague 2, Czech Republic.

Hana Vlášková (H)

Department of Paediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 2, 120 00, Prague 2, Czech Republic.

Eva Košťálová (E)

Department of Paediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 2, 120 00, Prague 2, Czech Republic.

Radim Mazanec (R)

Department of Neurology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.

Alena Zumrová (A)

Department of Paediatric Neurology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.

Petr Mečíř (P)

Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Zuzana Mušová (Z)

Department of Biology and Medical Genetics, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.

Martin Magner (M)

Department of Paediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 2, 120 00, Prague 2, Czech Republic. martin.magner@vfn.cz.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH